Oncology
Gastroesophageal Junction Cancer
0
Pipeline Programs↗
12
Active Trials↗
11
Companies Involved↗
Gastroesophageal Junction Cancer is an early-stage landscape with 0 programs across 11 companies. The most active players are Bristol-Myers Squibb, Amgen, Kuhnil Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
56
clinical trials
Completed30 · 54%
Terminated9 · 16%
Recruiting6 · 11%
Active, not recruiting5 · 9%
Unknown status5 · 9%
Not yet recruiting1 · 2%
Clinical Trials
Trial Activity
56 trials
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Recruiting·—·Phase 2·NCT07315854·32 enrolled
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Recruiting·—·Phase 2·NCT04660760·116 enrolled
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Active, not recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03760822·112 enrolled
Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:
Not yet recruiting·—·Phase 3·NCT06411171·36 enrolled
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
Completed·—·Phase 2·NCT00268346·58 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)